Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2021
ENDRA appoints Irina Pestrikova as Senior Director of Finance
ENDRA Life Sciences announced Irina Pestrikova’s appointment as Senior Director of Finance and Principal Financial Officer. She will assume the day-to-day responsibilities previously performed by CFO David Wells.
2021
ENDRA announces CFO David Wells’s departure
ENDRA announced that CFO David Wells would leave the company effective June 18, 2021, to pursue another opportunity. He was to continue supporting ENDRA as a consultant through September 2021 to assist with the transition.
2021
ENDRA Life Sciences reports first-quarter 2021 results
ENDRA Life Sciences reported financial results for the three months ended March 31, 2021, including a net loss of $2.3 million.
2021
ENDRA announces clinical study partnership with Inselspital University Hospital
ENDRA Life Sciences announced a partnership with Inselspital University Hospital in Bern for a clinical study of ENDRA's TAEUS device to assess non-alcoholic fatty liver disease.
2020
ENDRA Life Sciences announces pricing of public stock offering
ENDRA Life Sciences announced pricing for an underwritten public offering of 7,143,000 common shares at $0.70 per share. The offering was expected to close on December 18, 2020, subject to customary closing conditions.
2020
ENDRA and CHU Angers announce a clinical study partnership
ENDRA Life Sciences announced that Centre Hospitalier Universitaire d'Angers is partnering with it on a clinical study evaluating ENDRA's TAEUS device for assessing NAFLD.
2020
ENDRA announces clinical-study partnership with MCW
ENDRA Life Sciences announced that the Medical College of Wisconsin was partnering with it on a clinical study of ENDRA's TAEUS device for assessing non-alcoholic fatty liver disease.
2020
ENDRA and GE Healthcare renew collaboration agreement
ENDRA Life Sciences announced that it renewed its collaboration agreement with GE Healthcare, extending the agreement's term to January 2021. GE Healthcare will continue supporting commercialization activities for ENDRA's TAEUS technology, while ENDRA will provide GE Healthcare certain rights of first offer related to manufacturing and licensing.